Description: NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of nerve damage. Its product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University of Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Home Page: www.nervgen.com
NGEN Technical Analysis
2955 Virtual Way
Vancouver,
BC
V5M 4X6
Canada
Phone:
778 731 1711
Officers
| Name | Title |
|---|---|
| Mr. William Joseph Radvak BASc | Co-Founder, Interim CEO & Exec. Chairman |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corp. Sec. |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer |
| Dr. Adam H. Rogers M.D. | Interim Pres & Director |
| Mr. Brian McAlister | Co-Founder & Advisor |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0989 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |